US EPA

The report summarizes and evaluates information relevant to a preliminary interim assessment of adverse health effects associated with specific chemicals or compounds. The Office of Emergency and Remedial Response (Superfund) uses these documents in preparing cost-benefit analyses under Executive Order 12991 for decision-making under CERCLA. All estimates of acceptable intakes and carcinogenic potency presented in the document should be considered as preliminary and reflect limited resources allocated to the project. The intent in these assessments is to suggest acceptable exposure levels whenever sufficient data are available. The interim values presented reflect the relative degree of hazard associated with exposure or risk to the chemical(s) addressed. Whenever possible, two categories of values have been estimated for systematic toxicants (toxicants for which cancer is not the endpoint of concern). The first, RfDS or subchronic reference dose, is an estimate of an exposure level that would not be expected to cause adverse effects when exposure occurs during a limited time interval. The RfD is an estimate of an exposure level that would not be expected to cause adverse effects when exposure occurs for a significant portion of the lifespan. For compounds for which there is sufficient evidence of carcinogenicity, q1*s have been computed, if appropriate, based on oral and inhalation data if available.

U.S. EPA. Health Effects Assessment for Bromomethane. U.S. Environmental Protection Agency, Washington, D.C., EPA/600/8-88/022 (NTIS PB88179478), 1987.

See also PB86-134111. repared in cooperation with Syracuse Research Corp., NY.